GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc. The company's drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma. It is also developing a Phase 1 clinical trial drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. It has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GLYC
CUSIPN/A
Phone240-243-1201
Debt
Debt-to-Equity RatioN/A
Current Ratio33.13
Quick Ratio33.13
Price-To-Earnings
Trailing P/E Ratio-14.00
Forward P/E Ratio-12.76
P/E GrowthN/A
Sales & Book Value
Annual Sales$20,000.00
Price / Sales34,060.46
Cash FlowN/A
Price / CashN/A
Book Value$3.49 per share
Price / Book4.53
Profitability
EPS (Most Recent Fiscal Year)($1.13)
Net Income$-33,280,000.00
Net MarginsN/A
Return on Equity-23.05%
Return on Assets-21.99%
Miscellaneous
Employees40
Outstanding Shares43,060,000
Market Cap$624.76 million
GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions
What is GlycoMimetics' stock symbol?
GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."
How were GlycoMimetics' earnings last quarter?
GlycoMimetics Inc (NASDAQ:GLYC) released its quarterly earnings results on Friday, August, 10th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.34) by $0.08. View GlycoMimetics' Earnings History.
When is GlycoMimetics' next earnings date?
What price target have analysts set for GLYC?
5 brokers have issued twelve-month price targets for GlycoMimetics' stock. Their forecasts range from $21.00 to $35.00. On average, they anticipate GlycoMimetics' share price to reach $28.00 in the next year. This suggests a possible upside of 77.2% from the stock's current price. View Analyst Price Targets for GlycoMimetics.
What is the consensus analysts' recommendation for GlycoMimetics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GlycoMimetics.
Who are some of GlycoMimetics' key competitors?
Some companies that are related to GlycoMimetics include Spectrum Pharmaceuticals (SPPI), Akorn (AKRX), Supernus Pharmaceuticals (SUPN), Myokardia (MYOK), Xencor (XNCR), Reata Pharmaceuticals (RETA), Cambrex (CBM), AnaptysBio (ANAB), Prestige Brands (PBH), Phibro Animal Health (PAHC), PTC Therapeutics (PTCT), Mirati Therapeutics (MRTX), G1 Therapeutics (GTHX), Pacira Pharmaceuticals (PCRX) and Clovis Oncology (CLVS).
Who are GlycoMimetics' key executives?
GlycoMimetics' management team includes the folowing people:
- Ms. Rachel K. King, Pres, CEO & Director (Age 59)
- Mr. Brian M. Hahn, CFO & Sec. (Age 44)
- Dr. John L. Magnani, Sr. VP of Research, Chief Scientific Officer & Director (Age 65)
- Dr. Helen M. Thackray, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 50)
- Mr. Henry Flanner, VP of Technical Operations
Has GlycoMimetics been receiving favorable news coverage?
Headlines about GLYC stock have trended somewhat positive on Tuesday, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. GlycoMimetics earned a media and rumor sentiment score of 0.13 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.36 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for GlycoMimetics.
Who are GlycoMimetics' major shareholders?
GlycoMimetics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (21.39%), FMR LLC (8.85%), OppenheimerFunds Inc. (6.97%), BlackRock Inc. (6.60%), Redmile Group LLC (4.71%) and Jennison Associates LLC (3.75%). Company insiders that own GlycoMimetics stock include Brian M Hahn, Daniel M Junius, Helen M Thackray and M James Barrett. View Institutional Ownership Trends for GlycoMimetics.
Which institutional investors are selling GlycoMimetics stock?
GLYC stock was sold by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, Redmile Group LLC, Millennium Management LLC, Janus Henderson Group PLC, Alps Advisors Inc. and Alps Advisors Inc.. Company insiders that have sold GlycoMimetics company stock in the last year include Brian M Hahn, Helen M Thackray and M James Barrett. View Insider Buying and Selling for GlycoMimetics.
Which institutional investors are buying GlycoMimetics stock?
GLYC stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., NEA Management Company LLC, OppenheimerFunds Inc., Citadel Advisors LLC, FMR LLC, Bank of New York Mellon Corp, Schwab Charles Investment Management Inc. and Swiss National Bank. View Insider Buying and Selling for GlycoMimetics.
How do I buy shares of GlycoMimetics?
Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GlycoMimetics' stock price today?
One share of GLYC stock can currently be purchased for approximately $15.80.
How big of a company is GlycoMimetics?
GlycoMimetics has a market capitalization of $624.76 million and generates $20,000.00 in revenue each year. The biotechnology company earns $-33,280,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. GlycoMimetics employs 40 workers across the globe.
How can I contact GlycoMimetics?
GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]
MarketBeat Community Rating for GlycoMimetics (NASDAQ GLYC)
MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote "Outperform" if you believe GLYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLYC will underperform the S&P 500 over the long term. You may vote once every thirty days.
